Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-STEAP1 antibody-drug conjugate ADRX-0405

An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) six transmembrane epithelial antigen of the prostate 1 (STEAP1) conjugated, through a protease-cleavable linker, to a topoisomerase 1 (TOP1) inhibitor payload, with potential antineoplastic activity. Upon administration of anti-STEAP1 ADC ADRX-0405, the antibody moiety targets and binds to STEAP1 expressed on tumor cells. Following receptor internalization and linker cleavage, the TOP1 inhibitor targets and inhibits the activity of DNA topoisomerase 1, thereby inhibiting DNA replication and resulting in cell cycle arrest and tumor cell apoptosis of STEAP1-overexpressing tumor cells. STEAP1 is overexpressed in a variety of cancers, including prostate cancer, while its expression in normal healthy tissue is limited.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-STEAP1 ADC ADRX-0405
anti-STEAP1/TOP1i ADC ADRX-0405
anti-STEAP1/topoisomerase I inhibitor ADC ADRX-0405
Code name:ADRX 0405
ADRX-0405
ADRX0405
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search